Why there were differences between the effects of combined AXP2258 and the SOCs is not clear at the moment but differences in responses to drug + SOC combinations in IPF trials are beginning to appear in the literature26. The gene discussed is UBXN11; the disease is idiopathic pulmonary fibrosis.